retatrutide vs mazdutide tirzepatide: comparing dual-agonist weight loss peptides Mazdutide: An emerging glucagon/GCG-like peptide-1

Comparing Their Molecular Design Although both peptides belong to the same general family, they were engineered with different research objectives

Bottom line first: you need a license in every state where your patients are located

Studies show that cost remains the primary deterrent to medication-assisted weight management, with patients delaying or abandoning treatment when out-of-pocket expenses exceed $300 monthly

In the SURMOUNT-1 trial, tirzepatide produced average weight loss of: 5 mg dose: 15.0% body weight reduction 10 mg dose: 19.5% body weight reduction 15 mg dose: 20.9% body weight reduction These results came from 72 weeks of carefully titrated, medically supervised treatment

The first successful Phase 3 result, from TRIUMPH-4, showed average weight loss of up to 71.2 pounds in adults with obesity and knee osteoarthritis

Organized by the player-level story, the picture looks like this